J
Jesper B. Andersen
Researcher at University of Copenhagen
Publications - 162
Citations - 9516
Jesper B. Andersen is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 44, co-authored 130 publications receiving 6923 citations. Previous affiliations of Jesper B. Andersen include University of Maryland Marlene and Stewart Greenebaum Cancer Center & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales,Jesus M. Banales,Jesus M. Banales,Jose J.G. Marin,Jose J.G. Marin,Angela Lamarca,Angela Lamarca,Pedro M. Rodrigues,Shahid A. Khan,Lewis R. Roberts,Vincenzo Cardinale,Guido Carpino,Jesper B. Andersen,Chiara Braconi,Diego F. Calvisi,Maria J. Perugorria,Maria J. Perugorria,Luca Fabris,Luca Fabris,Luke Boulter,Rocio I.R. Macias,Rocio I.R. Macias,Eugenio Gaudio,Domenico Alvaro,Sergio A. Gradilone,Mario Strazzabosco,Mario Strazzabosco,Marco Marzioni,Cédric Coulouarn,Laura Fouassier,Chiara Raggi,Pietro Invernizzi,Joachim C. Mertens,Anja Moncsek,Sumera Rizvi,Julie K. Heimbach,Bas Groot Koerkamp,Jordi Bruix,Jordi Bruix,Alejandro Forner,Alejandro Forner,John Bridgewater,Juan W. Valle,Juan W. Valle,Gregory J. Gores +44 more
TL;DR: This expert Consensus Statement, endorsed by the ENS-CCA, summarizes the latest advances in CCA, including classification, genetics and treatment, and provides recommendations for CCA management and priorities across basic, translational and clinical research.
Journal ArticleDOI
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales,Vincenzo Cardinale,Guido Carpino,Marco Marzioni,Jesper B. Andersen,Pietro Invernizzi,Guro Elisabeth Lind,Trine Folseraas,Stuart J. Forbes,Laura Fouassier,Andreas Geier,Diego F. Calvisi,Joachim C. Mertens,Michael Trauner,Antonio Benedetti,Luca Maroni,Javier Vaquero,Rocio I.R. Macias,Chiara Raggi,Maria J. Perugorria,Eugenio Gaudio,Kirsten Muri Boberg,Jose J.G. Marin,Domenico Alvaro +23 more
TL;DR: This Consensus Statement aims to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer.
Journal ArticleDOI
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.
Cédric Coulouarn,Valentina M. Factor,Jesper B. Andersen,Marian E. Durkin,Snorri S. Thorgeirsson +4 more
TL;DR: It is reported that miR-122 is specifically repressed in a subset of primary tumors that are characterized by poor prognosis, and it is shown that loss of microRNA-122 results in an increase of cell migration and invasion and that restoration of mi R-122 reverses this phenotype.
Journal ArticleDOI
Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
Jesper B. Andersen,Bart Spee,Boris Blechacz,Itzhak Avital,Mina Komuta,Andrew Barbour,Elizabeth A. Conner,Matthew C. Gillen,Tania Roskams,Lewis R. Roberts,Valentina M. Factor,Snorri S. Thorgeirsson +11 more
TL;DR: Insight into the pathogenesis of cholangiocarcinoma is provided and previously unrecognized subclasses of patients, based on KRAS mutations and increased levels of EGFR and HER2 signaling, who might benefit from dual-target tyrosine kinase inhibitors are identified.
Journal ArticleDOI
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients
Luca Quagliata,Matthias S. Matter,Salvatore Piscuoglio,Salvatore Piscuoglio,Leila Arabi,Christian Ruiz,Alfredo Procino,Michal Kovac,Francesca Moretti,Zuzanna Makowska,Tujana Boldanova,Jesper B. Andersen,Monika Hämmerle,Luigi Tornillo,Markus H. Heim,Sven Diederichs,Clemente Cillo,Luigi Terracciano +17 more
TL;DR: It is demonstrated that the levels of HOTTIP and HOXA13 are associated with HCC patients' clinical progression and predict disease outcome, and novel insights on the function of lncRNA‐driven hepatocarcinogenesis are provided.